Else Nutrition Holdings Inc (OTCQX:BABYF, TSX-V:BABY) CEO Hamutal Cohen Yitzhak tells Proactive's Stephen Gunnion that a number of catalyst lie ahead for the company this year, including the launch of its 'ready-to-drink' infant nutrition in the US, its entry to the UK market as a starting point for Europe and Australia as a gateway to China.
Importantly, she said the company remains on track to begin its infant growth clinical study for the FDA and European permits. Receiving FDA approval is a very high priority for Else Nutrition, as it believes that becoming the first non-dairy and non-soy FDA-approved infant formula will be transformational.
Yitzhak also commented on Else's first-quarter results, which showed an 80% year-over-year increase in revenue to $2.9 million.